References
Huang BT, Peng Y, Huang FY et al (2017) Trends in prescribing rate of statins at discharge and modifiable factors in patients with atherosclerotic cardiovascular disease. Intern Emerg Med. doi:10.1007/s11739-017-1694-9 (Epub ahead of print)
Maddox TM, Borden WB, Tang F et al (2014) Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol 64:2183–2192
Shah NS, Huffman MD, Ning H, Lloyd-Jones DM (2015) Trends in myocardial infarction secondary prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999–2012. J Am Heart Assoc 4:e001709
Subherwal S, Patel MR, Kober L et al (2012) Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation 126:1345–1354
Guglielmi V, Bellia A, Pecchioli S et al (2017) Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care. Atherosclerosis 263:36–41
Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670–1681
Gupta A, Thompson D, Whitehouse A et al (2017) Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 389:2473–2481
Catapano AL, Graham I, De Backer G et al (2016) ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the european association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J 37:2999e3058
Drozda JP Jr, Ferguson TB Jr, Jneid H et al (2016) 2015 ACC/AHA focused update of secondary prevention lipid performance measures: a report of the American College of Cardiology/American Heart Association Task Force on performance measures. J Am Coll Cardiol 67:558–587
Gæde P, Vedel P, Larsen N et al (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393
Cramer JA, Mattson RH, Prevey ML et al (1989) How often is medication taken as prescribed? A novel assessment technique. JAMA 261:3273–3277
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Statement of human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
None.
Rights and permissions
About this article
Cite this article
Bellia, A., Della-Morte, D. & Lauro, D. Suboptimal use of statins for secondary cardiovascular prevention: a “planetary” issue. Intern Emerg Med 12, 1091–1092 (2017). https://doi.org/10.1007/s11739-017-1749-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-017-1749-y